A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
OBJECTIVE
To compare continuous combined hormone replacement therapy (ccHRT) and raloxifene with respect to compliance and quality of life, which were predefined secondary endpoints of a large, prospective study designed to investigate the uterine effects of both treatments.


METHODS
Double-blind, randomised controlled trial of six-month duration.


METHODS
One hundred and twenty-nine gynaecology hospital departments, clinics or practices specialised in women's healthcare, located in Europe, South Africa and Israel.


METHODS
Healthy postmenopausal women (n = 1008).


METHODS
Changes in quality of life using the Women's Health Questionnaire (WHQ) and compliance using a compliance questionnaire and pill count. Adverse event and early discontinuation rates and satisfaction with treatment using a visual analogue scale (VAS).


RESULTS
Women taking raloxifene reported greater satisfaction with their treatment as assessed on the VAS (P = 0.004), and a lower proportion, as compared with ccHRT, reported being worried by the treatment (9.6% vs 20.2%, P < 0.01). Women taking ccHRT reported greater deterioration in scores from the WHQ for depressed mood and menstrual symptoms than those taking raloxifene (P < 0.01). For memory, vasomotor symptoms and sexual behaviour, the ccHRT group reported significantly greater mean improvements (P < 0.05). Over half (58.8%) of those taking raloxifene noticed no effect, 37.7% felt better and 3.4% felt worse as measured using the compliance questionnaire. Fifty percent of the women taking ccHRT felt better, 37.8% noticed no effect but over 10% felt worse. More women on raloxifene (94.6%) than on ccHRT (85.9%) reported that they were taking their double-blinded medication regularly (P < 0.01).


CONCLUSIONS
A lower rate of adverse event-related discontinuations, the lack of negative effects on quality of life and a smaller proportion of women being worried by the drug treatment were associated with higher treatment satisfaction and better compliance in postmenopausal women taking ccHRT or raloxifene.
Eli Lilly & Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK.
Simon
S
Voss
Deborah
D
Quail
Alison
A
Dawson
Tjorbörn
T
Bäckström
Fernanda
F
Aguas
Mithat
M
Erenus
Hok Sien
HS
The
John
J
Bonnar
Christian
C
De Geyter
Myra
M
Hunter
Thomas
T
Nickelsen
D000368:Aged; D001941:Breast Diseases / Q000139:chemically induced; D004311:Double-Blind Method; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D010349:Patient Compliance; D017060:Patient Satisfaction; D017698:Postmenopause; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016312:Treatment Refusal; D014664:Vasodilation / Q000187:drug effects
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride